# A Study to Evaluate the Efficacy and Safety of Eptinezumab for the Prevention of Migraine in Participants That Are Not Helped by Previous Preventive Treatments

> **NCT04418765** · PHASE3 · COMPLETED · sponsor: **H. Lundbeck A/S** · enrollment: 892 (actual)

## Conditions studied

- Migraine

## Interventions

- **DRUG:** Eptinezumab
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT04418765
- **Lead sponsor:** H. Lundbeck A/S
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-01
- **Primary completion:** 2021-07-15
- **Final completion:** 2022-09-15
- **Target enrollment:** 892 (ACTUAL)
- **Last updated:** 2023-09-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04418765

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04418765, "A Study to Evaluate the Efficacy and Safety of Eptinezumab for the Prevention of Migraine in Participants That Are Not Helped by Previous Preventive Treatments". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04418765. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*